PharmaBlock Sciences (Nanjing), Inc.'s (SZSE:300725) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
PharmaBlock Sciences (Nanjing) (SZSE:300725) has had a rough week with its share price down 6.5%. However, stock prices are usually driven by a company's financials over the long term, which in this
Pharmaceutical Stone Technology (300725.SZ): A one-stop innovative CRDMO service provider in the field of global pharmaceutical R&D and manufacturing
Gelonghui March 29丨Pharmaceutical Stone Technology (300725.SZ) said on the investor interactive platform that our company is a one-stop innovative CRDMO service provider in the field of global pharmaceutical R&D and manufacturing. The company helps drug discovery with its novel and unique molecular blocks and related compound library screening technology; and has built an integrated CRDMO service platform to provide process development and production services for efficient and high-quality intermediates, APIs and pharmaceutical preparations for innovative drug development and commercialization projects. The specific products and services provided by the company mainly depend on the partner's project requirements.
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
NANJING, China, March 26, 2024 /PRNewswire/ -- PharmaBlock (Stock code: 300725.SZSE), a global, fully integrated CRDMO with a focus on innovative chemistry and low-carbon manufacturing, is proud to an
Yakshi Technology won the 2024 ACS CMO Green Chemistry Excellence Award
Nanjing, March 26, 2024 /PRNewswire/ -- Nanjing Pharmaceutical Technology Co., Ltd. (Company abbreviation: “Pharmaceutical Stone Technology”, stock code: 300725.SZSE), as a global integrated CRDMO company focusing on innovative chemistry and low-carbon manufacturing, recently won the American Chemical Society (ACS) Green Chemistry Institute Pharmaceutical Roundtable (Green Chemistry Institute Pharmaceutical) Roundtable,
Optimistic Investors Push PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Shares Up 30% But Growth Is Lacking
Those holding PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) shares would be relieved that the share price has rebounded 30% in the last thirty days, but it needs to keep going to repair the recen
These 4 Measures Indicate That PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
PharmaBlock Sciences (Nanjing), Inc.'s (SZSE:300725) Earnings Haven't Escaped The Attention Of Investors
With a median price-to-earnings (or "P/E") ratio of close to 30x in China, you could be forgiven for feeling indifferent about PharmaBlock Sciences (Nanjing), Inc.'s (SZSE:300725) P/E ratio of 29.2x.
[BT Financial Report Momentary Analysis] Yakshi Technology's 2023 Quarterly Report: Financial Perspectives Behind Steady Growth in Performance
Pharmaceutical Stone Technology (stock code: 300725), as a global leader in pharmaceutical R&D and manufacturing, provides one-stop services from molecular block development to drug discovery solutions. The company focuses on chemical and low-carbon technology innovation, and is committed to improving the efficiency of new drug discovery and development while reducing drug production costs. Yakshi Technology's molecular block library is rich in variety, novel in structure and efficient, and has successfully covered many key stages of new drug development. In terms of assets and liabilities, Yakshi Technology's 2023 three-quarter report shows that the company's total assets reached 5.217 billion yuan, up from 4.862 billion yuan at the end of the previous year
Pharmaceutical Stone Technology (300725.SZ): As of December 29, 2023, the number of shareholders of the company was 30,363
Gelonghui, January 5, 丨 Yakshi Technology (300725.SZ) said on the investor interactive platform that as of December 29, 2023, the number of shareholders of the company was 30,363.
Pharmaceutical Stone Technology (300725.SZ): A total cost of 2002.23 million yuan to buy back 506,300 shares
Gelonghui, January 2, 丨 Pharmaceutical Stone Technology (300725.SZ) announced that as of December 31, 2023, the company had repurchased 506,300 shares through a dedicated securities account, accounting for 0.2536% of the company's current total share capital. The highest transaction price was 46.00 yuan/share, the minimum transaction price was 38.04 yuan/share, and the payment amount was 2.023 million yuan (not including transaction fees).
PharmaBlock Sciences (Nanjing), Inc.'s (SZSE:300725) 5.0% Gain Last Week Benefited Both Retail Investors Who Own 50% as Well as Insiders
Key Insights Significant control over PharmaBlock Sciences (Nanjing) by retail investors implies that the general public has more power to influence management and governance-related decisions 49% o
PharmaBlock Opens HPAPI GMP Facility at Zhejiang Manufacturing Site
NANJING, China, Dec. 27, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon
PharmaBlock Obtained ISO 50001 Certification, Advancing Sustainable Development
NANJING, China, Dec. 26, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725. SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon
Declining Stock and Decent Financials: Is The Market Wrong About PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725)?
With its stock down 5.9% over the past month, it is easy to disregard PharmaBlock Sciences (Nanjing) (SZSE:300725). But if you pay close attention, you might find that its key financial indicators l
Pharmaceutical Stone Technology (300725.SZ): Repurchased 43,200 shares at a total cost of 1,937,704 million yuan
Gelonghui Technology (300725.SZ) announced on December 4 | Yakushi Technology (300725.SZ) announced that as of November 30, 2023, the company has repurchased 43,200 shares through centralized bidding transactions through special repurchase securities accounts, accounting for 0.022% of the company's current total share capital. The maximum transaction price is 4600 yuan/share, the minimum transaction price is 44.12 yuan/share, and the payment amount is 1,9370.04 million yuan (excluding transaction fees).
Pharmaceutical Stone Technology (300725.SZ): Currently not involved in CRISPR gene editing related business
Gelonghui November 24丨Pharmaceutical Stone Technology (300725.SZ) stated on the investor interactive platform that the company is currently not involved in CRISPR gene editing related business. The company closely followed various innovative technologies in the field of targeted protein degradation (TPD), designed and developed novel CRBN ligands using the company's unique master molecular blocks, and promoted them to the market, which received good feedback. The company has also provided API synthesis process development and production services, formulation process development and production services for a number of targeted protein degradation chimeric projects. Some projects have already entered clinical phase I and phase II.
Pharmaceutical Stone Technology (300725.SZ): The initial repurchase of 13,200 shares involved 606,500 yuan
Gelonghui November 21丨Yakushi Technology (300725.SZ) announced that on November 21, 2023, the company implemented share repurchases through a centralized bidding transaction through a special stock repurchase account. The number of shares repurchased was 13,200 shares, accounting for 0.0066% of the company's current total share capital. The maximum transaction price is 46 yuan/share, the lowest transaction price is 45.77 yuan/share, and the total transaction amount is 6064.78 million yuan (excluding transaction fees).
Positive Earnings Growth Hasn't Been Enough to Get PharmaBlock Sciences (Nanjing) (SZSE:300725) Shareholders a Favorable Return Over the Last Three Years
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But its virtually certain that sometimes you will buy stocks that fall
Pharmaceutical Stone Technology (300725.SZ): No share repurchases yet
Gelonghui November 2 | Pharmaceutical Stone Technology (300725.SZ) announced that as of October 31, 2023, the company has not carried out a share repurchase.
Pharmaceutical Stone Technology (300725.SZ): Huishi's high-activity kilogram production line is expected to be ready for use by the end of November
Gelonghui November 1 | Pharmaceutical Stone Technology (300725.SZ) was surveyed by investors on October 30, 2023, on “Drug demand for new molecular entities such as ADCs and peptides, matching customer and production capacity?” The company replied that the company continues to strengthen capacity building for the development of new molecular physical drugs, and that a number of ADCs and peptides are currently being promoted. On the ADC side, the laboratory currently has the research and development capabilities of OEB4 and OEB5. Huishi's high-activity kilogram production line is expected to be ready for use by the end of November; in terms of peptides, the R&D team and R&D equipment are already in place to meet the kilogram level of R&D
No Data